Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Titel:
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Auteur:
Robichaux, Jacqulyne P. Elamin, Yasir Y. Vijayan, R.S.K. Nilsson, Monique B. Hu, Lemei He, Junqin Zhang, Fahao Pisegna, Marlese Poteete, Alissa Sun, Huiying Li, Shuai Chen, Ting Han, Han Negrao, Marcelo Vailati Ahnert, Jordi Rodon Diao, Lixia Wang, Jing Le, Xiuning Meric-Bernstam, Funda Routbort, Mark Roeck, Brent Yang, Zane Raymond, Victoria M. Lanman, Richard B. Frampton, Garrett M. Miller, Vincent A. Schrock, Alexa B. Albacker, Lee A. Wong, Kwok-kin Cross, Jason B. Heymach, John V.